Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics
解读5位分析师对y-mabs therapeutics的评价
The standing of Y-mAbs Therapeutics...Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics (NASDAQ:YMAB), expressing a variety of opinions spanning from bullish to bearish.
在最近的三个月里，5位分析师分享了他们对y-mabs therapeutics（纳斯达克：YMAB）的见解，表达了从看好到看淡的多种观点。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
以下表格总结了他们最近的评级，揭示了过去30天内情绪的变化，并将其与前几个月进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $21.0, a high estimate of $23.00, and a low estimate of $17.00. Experiencing a 3.09% decline, the current average is now lower than the previous average price target of $21.67.
分析师对12个月价格目标的洞察显示，平均目标为21.0美元，高位估计为23.00美元，低位估计为17.00美元。目前的平均水平下降了3.09%，现行平均值低于之前的平均价格目标21.67美元。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查：一项详尽的研究
The standing of Y-mAbs Therapeutics...
y-mabs...
登录免费看全文
登录/注册
资讯热榜
更新时间